Een PEA-houdend product (pamitoylethanolamide): abundant clinical literature

Many patients and physicians ask about studies done to demonstrate the efficacy and safety of een PEA-houdend product in pain and inflammation.

Ten years ago, it was already stated that palmitoylethanolamide was an intersting treatmentoption for pain and inflammation. Meanwhile, we have seen many hundreds of studies supporting this idea.[1][2][3]

Many clinical studies have supported its use in dermatitis and other inflammatory states, and a multitude of painstates. [4] [5] [6] [7][8][9][10][11] [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]

Even in animals vets have seen clinical meaningful efficacy.[30][31][32][33][31]

And een PEA-houdend product is an endocannabinoid. read this, quite interesting indeed! :

Endocannabinoids as molecular instruments of health promotion
Esch T, Michalsen A, Stefano GB.
Studiengang der Integrierenden Gesundheitsforderung,
Hochschule fur Angewandte Wissenschaften Coburg,
Friedrich-Streib-Str. 2, D-96450 Coburg.
Med Monatsschr Pharm. 2006 Nov;29(11):397-403.


Endocannabinoids may be a physiological model for our self-healing capacities, since they are part of a complex system of natural auto-regulatory processes. This system has been examined via neurobiology, where the experimental invertebrate model is useful. Endocannabinoids, as well as endogenous morphine, activate constitutive nitric oxide (NO) release, which exerts a variety of positive physiological effects. By doing so, we surmise endogenous stress reduction emerges. Therefore, in the context of endocannabinoid auto-regulation, it seems adequate to speak of “health promotion on a molecular level”. The convergence of endogenous auto-regulation on NO pathways critically relies upon common or overlapping neurobiological molecular components, as they are represented by limbic reward and motivation mechanisms. To our knowledge, endogenous auto-regulation–involving deep limbic brain activities–plays a crucial role in successful modern strategies of applied and integrative health promotion. More research, however, is necessary before the different aspects of neurobiological science and clinical medicine in the field of prevention may be integrated extensively and with profound reason. Conclusions: Successful preventive programs, such as integrative medical stress management, include auto-regulative mechanisms on the physiological level. This leads to an interesting research potential, particularly when one considers the long-term effects of applied health promotion and its coupling to motivational neurobiological phenomena.

[1]: Calignano A, La Rana G, Giuffrida A, Piomelli D. | Control of pain initiation by endogenous cannabinoids. | Nature. | 1998 Jul 16;394(6690):277-81.
[2]: De Petrocellis L, Melck D, Bisogno T, Di Marzo V. | Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. | Chem Phys Lipids. | 2000 Nov;108(1-2):191-209.
[4]: G. Guida, A. de Fabiani, F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai, S. Petrosino | La palmitoiletanolamida en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. | Dolor | 2010, 25:35-42
[5]: Biasiotta A, La Cesa S, Leone C, Di Stefano G, Truini A, Cruccu G. | Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clincial and neurophysiological open study. Preliminary results. | , Volume 4, Issue 1, May 2010, Page 77. |
[6]: Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, Ratto S. | P1577: The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide | Eur J Neurol | 2010: 17(S3):295.
[7]: Bortolotti F,Russo M, Bartolucci ML, Alessandri Bonetti G, Gatto MR, Marini I. | Palmitoylethanolamide vs NSAID in the treatment of TMJD Pain | Journal of Dental Research | 2010: 89(Special Issue B)
[8]: Phan NQ, Siepmann D, Gralow I, Ständer S. | Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. | J Dtsch Dermatol Ges. | 2010 Feb;8(2):88-91. Epub 2009 Sep 10.
[9]: Indraccolo U, Barbieri F. | Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. | Eur J Obstet Gynecol Reprod Biol. | 2010 May;150(1):76-9. Epub 2010 Feb 21.
[10]: Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. | Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. | Pain Med. | 2010 May;11(5):781-4. Epub 2010 Mar 22.
[11]: Kopsky DJ, Hesselink JM. | Nerve regeneration in neuropathic pain. | Pain Med. | 2010 Oct;11(10):1576. doi: 10.1111/j.1526-4637.2010.00947.x. Epub 2010 Sep 7.
[12]: Hurych J, Holusa R, Effenbergerová E, Mirejovská E. | Attempt to influence silicotic fibrosis by means of N-(2-hydroxyethyl) palmitamide (Impulsin). | Czech Med. | 1980;3(3):218-25.
[13]: Masek K, Perlík F, Klíma J, Kahlich R. | Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. | Eur J Clin Pharmacol. | 1974 Oct 4;7(6):415-9.
[14]: Kahlich R, Klíma J, Cihla F, Franková V, Masek K, Rosický M, Matousek F, Bruthans J. | Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. | J Hyg Epidemiol Microbiol Immunol. | 1979;23(1):11-24.
[16]: Eberlein B, Eicke C, Reinhardt HW, Ring J. | Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). | J Eur Acad Dermatol Venereol. | 2008 Jan;22(1):73-82.
[18]: Pulvirenti N, Nasca MR, Micali G. | Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. | Acta Dermatovenerol Croat. | 2007;15(2):80-3.
[19]: P,Deslo. Combination of pregabalin and palmitoylethanolamide (PEA) for neuropathic pain treatment. | Pathos, 2010, 17,4:9-14 | |
[20]: Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. | Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. | Minerva Med. | 2011 Apr;102(2):141-7.
[21]: Christian Bacci, Giulia Cassetta, Bruno Emanuele, and Mario Berengo | Research Article Randomized Split-Mouth Study on Postoperative Effects of Palmitoylethanolamide for Impacted Lower Third Molar Surgery | Volume 2011: Article ID 917350, 6 pages doi:10.5402/2011/917350 |
[24]: Petrosino S, Iuvone T, Di Marzo V. | N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. |Biochimie. | 2010 Jun;92(6):724-7. Epub 2010 Jan 21.
[25]: Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D’Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. | Protective role of palmitoylethanolamide in contact allergic dermatitis. | Allergy. | 2010 Jun 1;65(6):698-711. Epub 2009 Nov 11.
[26]: Ständer S, Reinhardt HW, Luger TA. | [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. | Hautarzt. | 2006 Sep;57(9):801-7.
[27]: Kemeny L, Koreck A, Kis K, Kenderessy-Szabo A, Bodai L, Cimpean A, Paunescu V, Raica M, Ghyczy M. | Endogenous phospholipid metabolite containing topical product inhibits ultraviolet light-induced inflammation and DNA damage in human skin. | Skin Pharmacol Physiol. | 2007;20(3):155-61. Epub 2007 Jan 17.
[28]: Hoareau L, Ravanan P, Gonthier MP, Delarue P, Gonçalves J, Césari M, Festy F, Roche R. | Effect of PEA on LPS inflammatory action in human adipocytes. | Cytokine. | 2006 Jun;34(5-6):291-6. Epub 2006 Aug 1.
[29]: Abramovits W, Perlmutter A. | Steroids versus other immune modulators in the management of allergic dermatoses. |Curr Opin Allergy Clin Immunol. | 2006 Oct;6(5):345-54.
[30]: Cerrato S, Brazis P, Valle MF, Miolo A, Petrosino S, Marzo VD, Puigdemont A. | Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. | Vet J. | 2011 May 19. [Epub ahead of print]
[33]: De Filippis D, D’Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T. | Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. | J Cell Mol Med. | 2009 Jun;13(6):1086-95. Epub 2008 Apr 18.
[35]: Pulvirenti N, Nasca MR, Micali G. | Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. | Acta Dermatovenerol Croat. | 2007;15(2):80-3.
[36]: Jorge LL, Feres CC, Teles VE. | Topical preparations for pain relief: efficacy and patient adherence. | J Pain Res. | 2010 Dec 20;4:11-24.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: